Compare Twist Bioscience Corp (TWST) vs Vanguard Ultra Short Bond ETF (VUSB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Vanguard Ultra Short Bond ETF — how do they compare? Twist Bioscience Corp trades at $125.52 (market cap $8.42B), while Vanguard Ultra Short Bond ETF trades at $47.55. The key difference: Twist Bioscience Corp is trading nearer its 52-week high, Vanguard Ultra Short Bond ETF nearer its low. Which is the better fit depends on your goals.
| TWST | VUSB | |
|---|---|---|
Market Cap | $8.42B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $153.10 | $50.03 |
52-Week Low | $24.16 | $49.55 |
Enterprise Value | $8.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
VUSB trades at $49.595 with minimal daily movement, showing a slight decline of 0.01%. The technical picture is bearish with moving averages signaling selling pressure, though oscillators suggest potential short-term recovery. Recent dividend distributions of $0.17-0.18 per share demonstrate consistent income generation. Market sentiment is influenced by Federal Reserve interest rate expectations favoring short-term bonds.
The outlook remains cautious with bearish technical indicators offset by positive sentiment around short-term bond strategies. Investment opportunity lies in the ETF's defensive positioning amid potential rate hikes, while risks include interest rate sensitivity and market volatility. The stock presents a conservative income play in uncertain monetary policy environments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Vanguard Ultra Short Bond ETF
VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →
